Vyndaqel (tafamidis)
$1,100.00
Vyndaqel (tafamidis) is a medication used for the treatment of transthyretin amyloidosis in adults with early-stage symptomatic polyneuropathy.
product price is per capsule.
What is Vyndaqel (tafamidis)?
Vyndaqel (tafamidis) is a medicine indicated for the treatment of transthyretin amyloidosis in patients with stage 1 symptomatic polyneuropathy to delay peripheral neurologic impairment[1]. Vyndaqel (tafamidis) is the first medication approved to stabilise the protein transthyretin (TTR) from misfolding and forming amyloids[3]. Buy Vyndaqel (tafamidis) Online.
It is available in capsule form each containing 20mg of tafamidis.
Who is Vyndaqel (tafamidis) for?
Vyndaqel (tafamidis) is indicated for adults with stage 1 transthyretin familial amyloid polyneuropathy (TTR-FAP).
Polyneuropathies, or peripheral neuropathies, result from damage to the peripheral nerves (nerves that go from the spinal cord to the arms, hands, legs, and feet[2]), which often result in a sense of weakness, numbness and pain in the extremities[1,4].
How does Vyndaqel (tafamidis) work?
Transthyretin amyloidosis is a rare disease characterised by the presence of a defective blood protein called transthyretin (TTR). This defective protein breaks easily, which results in the deposition of a fibrous substance (amyloid fibrils) within the body[5]. The accumulation of amyloid fibrils causes damage to body structures, like tissues and organs, and prevents their normal function[5]. When the nerves are affected the disease is called transthyretin familial amyloid polyneuropathy (TTR-FAP)[10].
The active substance in Vyndaqel, tafamidis, is a transthyretin stabiliser. It attaches to transthyretin, the defective protein, and makes it stable. In this way, it prevents the protein from breaking up, and it may thus stop the formation of amyloid fibrils and slow down the progression of the neurological disorder[5].
Where has Vyndaqel (tafamidis) been approved?
Vyndaqel (tafamidis) has been approved for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP) by the:
- EMA (EU), November 2011[1]
- FDA (USA), May 2019[7]
- Health Canada, January 2020[11]
- PMDA (Japan), September 2013[12]
- TGA (Australia), March 2020[13]
Please note that this medicine may have also been approved in other regions than the ones we’ve listed. If you have a question about its approval in a specific country feel free to contact our support team for assistance. Buy Vyndaqel (tafamidis) Online.
Please be aware that any decision to use a prescription generic or brand name medicine should always be taken in consultation with a medical professional. The FDA has sent warning letters to drugmakers in India concerning the quality of their medicines.
How is Vyndaqel (tafamidis) taken?
The standard dosage is:
- 20 mg orally once daily[1].
Note: Please consult with your treating doctor for personalised dosing.
Are there any known side effects or adverse reactions of Vyndaqel (tafamidis)?
Possible Side Effects
The most common adverse reactions listed in the prescribing information include[1]: